First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. - Test2 - elhamkhani - TriplyDB

First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

http://www.wikidata.org/entity/Q33845881

about

Rising antipsychotic prescriptions for children and youth: cross-sectoral solutions for a multimodal problem Therapeutic approaches for shankopathies Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth A Qualitative Study of Antipsychotic Medication Experiences of Youth Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth.Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment.Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.System struggles and substitutes: A qualitative study of general practitioner and psychiatrist experiences of prescribing antipsychotics to children and adolescents Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain.SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics.Review of the pharmacotherapy of irritability of autism.A Pilot Study for Understanding the Perceptions of Australian General Practitioners Regarding Psychopharmacology for Children With Autism Spectrum Disorders.Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project.The need for a proper definition of a "treatment refractoriness" in tourette syndrome.Atypical antipsychotics for psychosis in adolescents.Q58775178 Second-generation antipsychotics in children: Risks and monitoring needs

P2860

Q27011438-D07FC25B-EF6C-4512-A24D-71A21D908296 Q27024976-728D9E5D-4BCD-43E6-85AA-D7080CD32931 Q34659629-E846874F-9B0F-4A7B-B9BD-A550C7E41893 Q34868848-91DAC615-9180-4E09-8EE8-5DC204BEECF4 Q34900812-C5D5506F-2B88-45AD-8D6B-42686EE173E4 Q35128405-4F369910-BF5B-4D79-BA89-647E7FC4ECDB Q35170541-91ECCF1D-5666-4C6B-9AD5-2D708D8F9369 Q35572650-55F6330B-160A-402D-8ABF-89CFD9201D56 Q36375877-7E79D4E9-C43C-4234-8BEF-C4FD3D3B3B2B Q37354917-AC486D4A-EC09-46D9-A761-14C3FE5566E0 Q37391342-0A98131D-1C50-4FC8-901E-BC4D4FBDB1A1 Q37515292-67F3D370-34B9-4C24-9FF2-77C335CB08B2 Q37724890-5019F453-5258-44A3-8C2F-C6539A4B5DFD Q38006705-953CF6CA-157A-4EF3-8FD1-AE0E10EC409D Q38877688-0BFBF642-3C59-4CA0-8928-5693833E73E8 Q41018102-C567F3F9-D2BD-4E4F-9B2B-EBB2635C2189 Q42715635-80672D38-61BA-4B46-B006-3F8FA287C3BD Q42975687-C93360C1-C970-4300-973E-DB3C43235BD4 Q58775178-9ADA40ED-AABF-426A-9F6A-956AAA7B66E1 Q58775220-0E9F8168-FF3F-46C4-82D7-985A8423F376

P2860

First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

http://www.wikidata.org/entity/Q33845881

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

First do no harm: promoting an ...... e in children and adolescents.

@ast

First do no harm: promoting an ...... e in children and adolescents.

@en

type

label

First do no harm: promoting an ...... e in children and adolescents.

@ast

First do no harm: promoting an ...... e in children and adolescents.

@en

prefLabel

First do no harm: promoting an ...... e in children and adolescents.

@ast

First do no harm: promoting an ...... e in children and adolescents.

@en

P1433

Q33845881-65ED52F7-5AED-4DEA-9E84-503FC99C3F4D

P1476

Q33845881-DF08C1F2-7C53-4227-A332-D854CE154D66

P2093

Q33845881-61BAA9B9-B234-4087-8C38-A65AB4AF9520

Q33845881-E04A3A7D-B17A-4961-A4EB-2AAB1F9FA38F

Q33845881-E204507F-45C2-4586-96D8-0E07A0B3CB0B

Q33845881-EBD452F8-DA9E-424E-8EDA-6FE3E728B364

Q33845881-FC13D552-0D2D-4CA6-A995-B8BFE23553C8

P2860

Q33845881-0378641C-499D-4897-9460-41DBCA8BE419

Q33845881-03AFAB5F-06D0-4D0E-8D5A-BF878D888D96

Q33845881-03FDCCD3-B99D-4FA0-A216-F4F5AC0465BF

Q33845881-085A71DC-AE0B-4D59-9F8D-4F9BFFCF1BFE

Q33845881-1114805E-DE2F-4517-B86D-2974A07ED68D

Q33845881-140A15FD-FE80-460A-9CA8-4D8201CB7E49

Q33845881-1455BA64-FEED-4C28-87E8-B157DDC8A0E1

Q33845881-154714B5-AC05-4881-82F0-EEA111CA32ED

Q33845881-17C6D16B-CEEB-4DE6-AF11-E2BAD706E878

Q33845881-199E1530-D8E7-41D0-BF1F-89970F978115

P304

Q33845881-D893530F-18F8-4042-A452-14C83EAF0CC4

P31

Q33845881-254F5A68-0018-4553-9AA0-2539BA197601

P433

Q33845881-89264E55-7A81-4F0F-A9EF-9DAACF9E25E8

P478

Q33845881-B053E3D8-D754-4C75-8521-F28A433C75CA

P577

Q33845881-4393776F-C2D4-4983-9905-254895AFA8F5

P698

Q33845881-ED3C1FBE-1D5A-430C-B796-1DB2BBF9FB67

P921

Q33845881-5CD3A45E-77A4-4DC4-8D17-8D02D99968CE

P932

Q33845881-D62D2047-0331-4C07-B30F-2A9F7729569C

P1433

Journal of the Canadian Academy of Child and Adolescent Psychiatry

P1476

First do no harm: promoting an ...... e in children and adolescents.

@en

P2093

Constadina Panagiotopoulos

http://www.w3.org/2001/XMLSchema#string

Dean Elbe

http://www.w3.org/2001/XMLSchema#string

Derryck H Smith

http://www.w3.org/2001/XMLSchema#string

Jana Davidson

http://www.w3.org/2001/XMLSchema#string

Rebecca Ronsley

http://www.w3.org/2001/XMLSchema#string

P2860

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

CDC growth charts: United States

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.

Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.

Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality

Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.

Hepatic injury due to troglitazone.

Risperidone in children with autism and serious behavioral problems.

P304

124-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20467549

http://www.w3.org/2001/XMLSchema#string

P921

P932

2868560

http://www.w3.org/2001/XMLSchema#string